Cargando…

Expression of c-Myc, Bcl2, Bcl6, and Cyclin D1 in High-Grade B-Cell Lymphoma

Background High-grade B-cell lymphomas (HGBLs), with c-Myc, Bcl2, and/or Bcl6 rearrangement, are aggressive neoplasms with poor clinical outcomes. Cyclin D1 is a proto-oncogene that is generally expressed by mantle cell lymphoma, its variants, and many other neoplasms. Aim The aim of this study is t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Seemal, Rathore, Zonaira, Jahangir, Fizza, Rafique, Zubaria, Chughtai, Akhtar S, Atiq, Aribah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Pathology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590381/ https://www.ncbi.nlm.nih.gov/pubmed/36312606 http://dx.doi.org/10.7759/cureus.29527

Ejemplares similares

Expression of SOX10 in Triple-Negative Breast Carcinoma in Pakistan
por: Ali, Seemal, et al.
Publicado: (2022)

Clinicopathological Features of Neuroendocrine Tumors in Gastroenteropancreatic Tract: A Single Center Study
por: Rafique, Zubaria, et al.
Publicado: (2022)

Morphological Spectrum of Glomerulonephritis in Medical Renal Biopsies: A Single-Center Study
por: Rafique, Zubaria, et al.
Publicado: (2022)

Histopathological Spectrum of Ovarian Neoplasms: A Single-Center Study
por: Batool, Ayma, et al.
Publicado: (2022)

Spectrum of Morphological and Immunofluorescence Patterns in Lupus Nephritis: A Single Institutional Study
por: Javeed, Saira, et al.
Publicado: (2022)

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)

Double-Expressor Phenotype (BCL-2/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation
por: Hashmi, Atif A, et al.
Publicado: (2021)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
por: Künstner, Axel, et al.
Publicado: (2021)

Four genetic lymphoma-specific events (MYC, BCL2, BCL6 and CCND1) identified in a high grade B lymphoma case
por: Ittel, A, et al.
Publicado: (2015)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment
por: Singh, Aditi, et al.
Publicado: (2022)

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
por: Mitobe, Masaki, et al.
Publicado: (2018)

DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction
por: Mitobe, Masaki, et al.
Publicado: (2021)

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
por: Witte, Hanno M., et al.
Publicado: (2023)

Clinicopathological Spectrum of B-Cell Non-Hodgkin Lymphoma in Pakistan Population: A Single-Center Study
por: Saleem, Rashida, et al.
Publicado: (2023)

MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)
por: Takeoka, Kayo, et al.
Publicado: (2022)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification
por: Miyaoka, Masashi, et al.
Publicado: (2022)

Redefining the high‐grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report
por: Rodríguez‐Pinilla, Socorro María, et al.
Publicado: (2021)

Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: a systematic review and meta-analysis
por: Zeremski, Vanja, et al.
Publicado: (2023)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

Primary CNS high-grade B-cell lymphoma, with rearrangements of MYC and BCL6 : a case report
por: Sasapu, Appalanaidu, et al.
Publicado: (2018)

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
por: Moore, Alison M., et al.
Publicado: (2018)

Invasive Micropapillary Carcinoma of the Breast With Solid Papillary Carcinoma: A Case Report
por: Khalid, Sohaib, et al.
Publicado: (2023)

MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy
por: Wang, Jiachen, et al.
Publicado: (2021)

P1232: PRINCIPLES OF PRECISION ONCOLOGY IN PRIMARY REFRACTORY HIGH-GRADE B-CELL LYMPHOMA WITH MYC-, BCL2 AND/OR BCL6 REARRANGEMENTS (HGBL-DH/TH)
por: Witte, H., et al.
Publicado: (2022)

High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia
por: Rogers, Thomas S, et al.
Publicado: (2019)

Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
por: Olschewski, Vito, et al.
Publicado: (2021)

Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy
Publicado: (2022)

DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
por: Akpa, Chidimma Agatha, et al.
Publicado: (2019)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas
por: Willenbacher, Ella, et al.
Publicado: (2020)

Targeting mitochondrial respiration and the BCL2 family in high‐grade MYC‐associated B‐cell lymphoma
por: Donati, Giulio, et al.
Publicado: (2021)

De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a case report and literature review
por: Uchida, Akiko, et al.
Publicado: (2017)

An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma
por: Javeed, Saira, et al.
Publicado: (2022)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
por: Mo, W., et al.
Publicado: (2022)

High‐grade B‐cell lymphoma with MYC and BCL2 rearrangements with abundant multinucleated giant tumor cells
por: Zhang, Man, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9ko9crii9iuj5lrvicsvle7jqi